The senior researcher at Seattle Children’s discussed the development and validation of A2-CAR-CISC EngTreg cells.
Subhash Tripathi, PhD
Advertisement
Articles by Subhash Tripathi, PhD
The senior researcher at Seattle Children’s discussed advantages of engineered Tregs compared with natural Tregs.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
FasTCAR Manufactured BCMAxCD19 CAR T-cell Therapy Shows Promise for Multiple Myeloma
2
Autologous Stem Cell Therapy for Alzheimer Disease Advances to Phase 2 After Positive Early Findings
3
FDA Approves BMS’s Liso-Cel for R/R Marginal Zone Lymphoma
4
ImmunoLogic, Episode 7: "Turbocharging CAR T-Cells: The IL-9 Orthogonal Signal" With Anusha Kalbasi, MD
5
